Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.critrevonc.2016.01.020 http://scihub22266oqcxt.onion/10.1016/j.critrevonc.2016.01.020 C4799732!4799732!26850575     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Crit+Rev+Oncol+Hematol 2016 ; 100 (ä): 117-26 Nephropedia Template TP {{tp|p=26850575|t=2016. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer |pdf=|usr=}}{{26850575}} gab.com Text Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer JO: Crit Rev Oncol Hematol http://www.kidney.de/pget.php?&tw=1&pmid=26850575 #FOAvip The management of metastatic colorectal cancer substantially improved over the last 10 years and median overall survival of patients might exceed 30 months. The selection of an effective first-line treatment represents a crucial point in order to achieve good outcome results. In the last years, the intensive FOLFOXIRI regimen in association with bevacizumab became a new standard option in this setting. In the present review we summarized the main steps of FOLFOXIRI regimen development from the first pilot study to the recent findings with biological agents, with a specific focus on practical aspects, such as patient?s selection, adverse event management, treatment schedules and post-progression strategies. Possible predictive markers, open issues and ongoing clinical trials have been also deeply described. Twit Text FOAVip Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer ????Crit Rev Oncol Hematol http://www.kidney.de/pget.php?&tw=1&pmid=26850575 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26850575 #FOAvip English Wikipedia <ref>{{Cite pmid|26850575}}</ref> Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer #MMPMID26850575 Sunakawa Y; Schirripa M; Lenz HJ Crit Rev Oncol Hematol 2016[Apr]; 100 (ä): 117-26 PMID26850575show ga The management of metastatic colorectal cancer substantially improved over the last 10 years and median overall survival of patients might exceed 30 months. The selection of an effective first-line treatment represents a crucial point in order to achieve good outcome results. In the last years, the intensive FOLFOXIRI regimen in association with bevacizumab became a new standard option in this setting. In the present review we summarized the main steps of FOLFOXIRI regimen development from the first pilot study to the recent findings with biological agents, with a specific focus on practical aspects, such as patient?s selection, adverse event management, treatment schedules and post-progression strategies. Possible predictive markers, open issues and ongoing clinical trials have been also deeply described. äUnderstanding the FOLFOXIRI-regimen to optimize treatment for metastat(epmc).pdf DeepDyve Pubget Overpricing